Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis
Open Access
- 19 June 2023
- journal article
- research article
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 29 (12) , 3815-3828
Abstract
Aims: The effects of FGF21 on Parkinson's disease (PD) and its relationship with gut microbiota have not been elucidated. This study aimed to investigate whether FGF21 would attenuate behavioral impairment through microbiota–gut–brain metabolic axis in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) induced PD mice model.Methods: Male C57BL/6 mice were rendomized into 3 groups: vehicle (CON); MPTP 30 mg/kg/day i.p. injection (MPTP); FGF21 1.5 mg/kg/d i.p. injection plus MPTP 30 mg/kg/day i.p. injection (FGF21 + MPTP). The behavioral features, metabolimics profiling, and 16 s rRNA sequencing were performed after FGF21 treatment for 7 days.Results: MPTP‐induced PD mice showed motor and cognitive deficits accompanied by gut microbiota dysbiosis and brain‐region‐specific metabolic abnormalities. FGF21 treatment dramatically attenuated motor and cognitive dysfunction in PD mice. FGF21 produced a region‐specific alteration in the metabolic profile in the brain in ways indicative of greater ability in neurotransmitter metabolism and choline production. In addition, FGF21 also re‐structured the gut microbiota profile and increased the relative abundance of Clostridiales, Ruminococcaceae, and Lachnospiraceae, thereby rescuing the PD‐induced metabolic disorders in the colon.Conclusion: These findings indicate that FGF21 could affect behavior and brain metabolic homeostasis in ways that promote a favorable colonic microbiota composition and through effects on the microbiota–gut–brain metabolic axis.Keywords
Funding Information
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
This publication has 45 references indexed in Scilit:
- Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control studyThe Lancet Neurology, 2017
- Reassessment of subacute MPTP-treated mice as animal model of Parkinson's diseaseActa Pharmacologica Sinica, 2017
- metabolic profiling of Parkinson's disease and mild cognitive impairmentMovement Disorders, 2017
- Cognitive decline in Parkinson diseaseNature Reviews Neurology, 2017
- FGF21 improves cognition by restored synaptic plasticity, dendritic spine density, brain mitochondrial function and cell apoptosis in obese-insulin resistant male ratsHormones and Behavior, 2016
- FGF21 Maintains Glucose Homeostasis by Mediating the Cross Talk Between Liver and Brain During Prolonged FastingDiabetes, 2014
- FGF21 regulates metabolism and circadian behavior by acting on the nervous systemNature Medicine, 2013
- QIIME allows analysis of high-throughput community sequencing dataNature Methods, 2010
- Diversity of human colonic butyrate‐producing bacteria revealed by analysis of the butyryl‐CoA:acetate CoA‐transferase geneEnvironmental Microbiology, 2010
- Protocol for the MPTP mouse model of Parkinson's diseaseNature Protocols, 2007